StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) stock

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$18.17−0.40 (-2.15%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Structure Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Structure Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $294.24M, up 79.8% year over year. For fiscal 2025 it was $225.26M, up 107.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$225.26M+107.0%
FY2024Dec 31, 2024$108.81M+55.2%
FY2023Dec 31, 2023$70.10M+93.7%
FY2022Dec 31, 2022$36.19M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$100.06M+82.9%
Q1 FY2026Mar 31, 2026$66.51M+55.1%
Q4 FY2025Dec 31, 2025$68.69M+105.1%
Q3 FY2025Sep 30, 2025$58.99M+81.0%
Q2 FY2025Jun 30, 2025$54.71M+148.1%
Q1 FY2025Mar 31, 2025$42.87M+107.3%
Q4 FY2024Dec 31, 2024$33.49M+67.1%
Q3 FY2024Sep 30, 2024$32.60M+86.1%
Q2 FY2024Jun 30, 2024$22.05M+13.6%
Q1 FY2024Mar 31, 2024$20.68M+57.4%
Q4 FY2023Dec 31, 2023$20.04M+139.7%
Q3 FY2023Sep 30, 2023$17.52M+91.2%
Q2 FY2023Jun 30, 2023$19.41M+90.7%
Q1 FY2023Mar 31, 2023$13.14M+54.7%
Q4 FY2022Dec 31, 2022$8.36M–
Q3 FY2022Sep 30, 2022$9.16M–
Q2 FY2022Jun 30, 2022$10.18M–
Q1 FY2022Mar 31, 2022$8.49M–

More Structure Therapeutics figures

See a number that looks wrong?